Telaprevir (TVR) is a protease inhibitor (PI) used in chronic hepatitis C treatment with pegylated interferon plus ribavirin. We analysed the prevalence and kinetic development of TVR resistance upon treatment.
Methods
A total of 24 cirrhotic patients (genotype 1a, n=8; genotype 1b, n=16) previously non-responders to standard therapy were treated with TVR-based therapy. The distribution of TVR-resistant variants was assessed at every HCV-RNA-positive time point by 454 ultra-deep pyrosequencing (UDPS) during a mean follow-up period of 9.4 months.
Results
A median of 6,837 reads/specimen was studied. Based on control UDPS, we considered mutations as real when present >0.4%. TVR-resistant variants were found at baseline in 8/24 patients (33.3%). Four of the 24 patients (16.7%), all genotype 1a, did not achieve HCV RNA<100 IU/ml between week (W)2 and W12 and stopped treatment. No statistical significant difference was observed in the prevalence of resistant mutants between responders and non-responders (25% [5/20] and 75% [3/4], respectively). The proportion of genotype 1a patients with R155K/T/Q at baseline was higher in non-responders than in responders (50% versus 0%). During treatment failure, significant enrichment in V36A/M and R155K/T/Q was observed but their frequency reverted back to baseline after TVR discontinuation.
Conclusions
TVR-resistant variants are widely present at baseline. The presence of TVR-resistant mutants at baseline, even in high abundance (>20%), did not always preclude TVR treatment success. The detection of R155K/T/Q at baseline may predict failure in genotype 1a patients. At failure, which occurred in genotype 1a patients, a significant enrichment in V36A/M and R155K/T/Q was observed.
References
1.
LinC., GatesC.A., RaoB.G.In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 23061. J Biol Chem2005; 280: 36784–36791.
2.
CuberoM., EstebanJ.I., OteroT.Naturally occurring NS3-protease inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology2008; 370: 237–245.
3.
ValletS., VironF., HenquellC.NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther2011; 16: 1093–1102.
4.
De MeyerS., DierynckI., GhysA.Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology2012; 56: 2106–2115.
5.
GoodmanD.D., ZhouY., MargotN.A.Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS2011; 25: 325–333.
6.
BucktonA.J., HarrisR.J., PillayD.HIV type-1 drug resistance in treatment-naïve patients monitored using minority species assays: a systematic review and meta-analysis. Antivir Ther2011; 16: 9–16.
7.
LiJ.Z., ParedesR., RibaudoH.Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA2011; 305: 1327–1335.
8.
BartelsD.J., ZhouY., ZhangE.Z.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naïve subjects. J Infect Dis2008; 198: 800–807.
9.
ChevaliezS., RodriguezC., SoulierA.Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. J Hepatol2011; 54Suppl 1: S30.
10.
HoweJ.A., QiuP., OgertR.A.Frequencies of resistance-associated amino acid variants detected by 454-sequencing during combination treatment with boceprevir plus peginterferon (peginterferon alfa-2b)/ribavirin in HCV (GT1)-infected patients. J Hepatol2011; 54Suppl 1: S176.
11.
SarrazinC., KiefferT., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007; 132: 1767–1777.
12.
SvarovskaiaE.S., MartinR., McHutchisonJ.G.Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol2012; 50: 3267–3274.
13.
HedskogC., MildM., JernbergJ.Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS ONE2010; 5: e11345.
14.
KiefferT.L., De MeyerS., BartelsD.J.Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE2012; 7: e34372.
15.
KiefferT.L., KwongA.D., PicchioG.R.Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother2010; 65: 202–212.
16.
ZeuzemS., SulkowskiM.S., ZoulimF.Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology2010; 52Suppl S1: 436A.
17.
ThomasX.V., de BruijneJ., SullivanJ.C.Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir. PLoS ONE2012; 7: e41191.
